Prof. Myung-Gyu Choi Profile

Prof. Myung-Gyu Choi

at Catholic Univ of Korea

SPIE Involvement:

Author

Publications (1)

This will count as one of your downloads.

You will have access to both the presentation and article (if available).

DOWNLOAD NOW

This content is available for download via your institution's subscription. To access this item, please sign in to your personal account.

Email or Username Forgot your username?

Password Forgot your password?

Show

Keep me signed in

No SPIE account? Create an account

Proceedings Article | 14 August 2019 Presentation

Photodynamic therapy followed by abraxane chemotherapy can significantly suppress pancreatic cancer metastasis (Conference Presentation)

Zhiming Mai, Myung-Gyu Choi, Tayyaba Hasan

Proceedings Volume 11070, 110705V (2019) https://doi.org/10.1117/12.2528195

KEYWORDS: Photodynamic therapy, Tumors, Pancreatic cancer, Cancer, Mouse models, Pancreas

Read Abstract +

It is estimated that metastasis is responsible for about 90% of cancer deaths. Therefore, the effective control of tumor progression and metastasis is crucial to decrease the patient mortality rate. The searching for effective regimens has become one of the hot research topics. Photodynamic therapy (PDT) has shown very promising in local control of pancreatic tumors, but had little impact in reducing tumor metastasis. We have been actively investigating the PDT-based combination treatment efficacies in orthotopic mouse models of human pancreatic cancers, and had previously found and reported that PDT followed by 4-time administrations with chemotherapeutic adjuvant abraxane could dramatically shrink primary pancreatic tumors, some of which even disappeared from the pancreas. In this study, we focused on the evaluation of treatment responses on metastasis inhibition with the same treatment regimen after two periods of time: short-term (24 days) and mid-term (60 days). The treatment regimen had the most suppressive effect on metastasis as compared with other control groups: 1) PBS, 2) Gemcitabine, 3) PDT, 4) abraxane, and 5) Gemcitabine + abraxane in both AsPC-1 and MIA PaCa-2 cell line models and for the short- and mid-term experimental courses. However, the triple combination therapy (this treatment regimen plus Gemcitabine) could not further increase the metastasis inhibition. Regression analysis for tumor weights and metastasis burden in any of the corresponding treatment groups suggested that there might not be a correlation between tumor size and metastasis, and the metastasis decrease might not be the results of tumor decrease upon the treatments.

My Library

You currently do not have any folders to save your paper to! Create a new folder below.

Folder Name

Folder Description

Conference Committee Involvement (1)

17th International Photodynamic Association World Congress

28 June 2019 | Cambridge, Massachusetts, United States

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks. You are receiving this notice because your organization may not have SPIE eBooks access.*

*Shibboleth/Open Athens users─please sign in to access your institution's subscriptions.

To obtain this item, you may purchase the complete book in print or electronic format on SPIE.org.

ORGANIZATIONAL
Sign in with credentials provided by your organization.

Organizational Username

Organizational Password

Show/Hide Password

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members:

Non-members: ADD TO CART

Keywords/Phrases

Search In:

Publication Years